Cannabis Report
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed 		Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board: 
Last Post: 6/18/2018 11:28:52 AM - Followers: 55 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

WARNING: 

A REVERSE SPLIT HAS OCCURRED!

Company description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001, known as Prexigebersen has completed a partial phase II combination trial (with LDAC). The interim results demonstrated 47% of the patients showed early anti-leukemic activity. The company is in the process of amending the dosing protocols for the combination trial and adding a Decitabine cohort.

http://www.biopathholdings.com/wp-content/uploads/2018/04/BPTH_Interim_Phase_2_AML_Data_Release.pdf 
 

The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully, because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive. Will the company apply for FDA acclerated status as interim testing is complete on 17 evaluable patients?

A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson but we are awaiting the FDA website comfirmation of same.

Patent protection for manufacturing their neutral lipid delivery system has been granted.

 
Bio-Path Holdings may also begin in 2018 phase 1 testing of their antisense drug Prexigebersen on certain types of uterine cancer. An IND using Prexigebersen for treatment resistent breast cancer may also occur.  Additionally, BPTH is initiating the development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected to occur in 2018. The third drug BP1003 which targets the Stat-3 protein, is expected to begin IND-enabling studies with a goal to enter first in-human trials in 2019 for treatment of pancreatic tumors.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there was some renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. At the present BPTH has no partnerships with drug manufacturers but if BPTH's delivery system and drugs continue to show promise partnerships are expected.

This link to the company website describes their delivery technology:

http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 5+ million in cash.

 
Bio-Path Holdings does not manufacture their drugs but uses contractors, hence the need for partners.
 
BPTH is presently traded on the NASDAQ.

Here are links to articles on their drug technology:

http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/wp-content/uploads/2017/06/Published-Article-Evolution-of-Antisense-in-Oncology.pdf

http://www.biopathholdings.com/wp-content/uploads/2018/03/BPTH_Lancet_20180329.pdf

Analyst coverage:
 
 
 
Cannabis Report
BPTH
Current Price
Volume:
Bid Ask Day's Range
BPTH Detailed Quote
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#3927   What is going on with this company? SJSTOCKSHARK 06/18/18 11:28:51 AM
#3926   after the reverse split i have 16,000k shares skybar27 06/14/18 07:47:37 PM
#3925   Sky, Are you still holding 32,000 shares? SJSTOCKSHARK 06/14/18 07:34:53 PM
#3924   its been over a year now and still skybar27 06/14/18 05:58:32 PM
#3923   Pstates, Prexigebersen is a drug which uses our SJSTOCKSHARK 06/14/18 10:32:36 AM
#3922   IMO You are correct in all of your PStates 06/14/18 09:46:52 AM
#3921   They are probably waiting until the stock is dmoffat 06/14/18 08:51:15 AM
#3920   Something is going to happen soon, the lights too simple 06/13/18 08:14:15 PM
#3919   But I thought if we stop the negativity dmoffat 06/13/18 01:16:02 PM
#3918   The company silence is deafening. Positive posting has SJSTOCKSHARK 06/13/18 12:27:51 PM
#3917   Dr. Younes must believe in the product. It tyburt 05/26/18 02:49:01 AM
#3916   I think it might be they are having tyburt 05/26/18 02:47:10 AM
#3915   I can't imagine that Dr. Younes would join Runninonempty 05/18/18 12:50:00 PM
#3914   I’m new here, so please tell me if tyburt 05/18/18 12:26:17 PM
#3913   I have been a fool about this company dmoffat 05/17/18 05:31:34 PM
#3912   The final post of the day. Once you SJSTOCKSHARK 05/17/18 03:08:25 PM
#3911   What events in the next year could cause SJSTOCKSHARK 05/17/18 01:42:32 PM
#3910   "As of March 31, 2018, the Company had SJSTOCKSHARK 05/17/18 10:44:23 AM
#3909   Here is the transcript: SJSTOCKSHARK 05/17/18 10:28:35 AM
#3908   SJ, looks like smoke and mirrors to me! Snug9 05/16/18 03:29:03 PM
#3907   Anyone listen to the 1st quarter results? SJSTOCKSHARK 05/16/18 10:41:22 AM
#3906   The 10Q is out! SJSTOCKSHARK 05/15/18 08:50:04 PM
#3905   Brettj, Your points are well taken but why SJSTOCKSHARK 05/13/18 06:43:58 PM
#3904   It might be that ARWR has a real Brettj 05/12/18 02:13:06 PM
#3903   ARWR an sRNA drug developer is now approaching SJSTOCKSHARK 05/11/18 06:35:04 PM
#3902   More News! SJSTOCKSHARK 05/10/18 02:24:39 PM
#3901   It looks like short interest is around 4.8% Gpheart2016 05/10/18 10:18:35 AM
#3900   I am curious to hear thoughts on this too simple 05/09/18 07:33:37 PM
#3899   GP, Because BPTH is now thinly traded what SJSTOCKSHARK 05/09/18 01:13:33 PM
#3898   News! HOUSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Bio-Path SJSTOCKSHARK 05/09/18 09:33:35 AM
#3897   GP, It looks like we have some buyers today. SJSTOCKSHARK 05/03/18 12:35:50 PM
#3896   Runin, I got the burn rate from the SJSTOCKSHARK 05/02/18 09:44:08 PM
#3895   As much as I enjoy cheering each other craiviolin 05/02/18 06:12:54 PM
#3894   That is good! We don’t want more iloveu2 05/02/18 05:37:27 PM
#3893   SJ, I think the burn rate is not Runninonempty 05/02/18 01:47:37 PM
#3892   When the news came out I almost bought vrock321 05/02/18 05:47:17 AM
#3891   Brettj, After your post I see why you SJSTOCKSHARK 05/01/18 04:00:52 PM
#3890   SJ, I'm not certain on the timeline for Brettj 05/01/18 03:05:53 PM
#3889   Brettj, Hopefully they are raising funds to develop SJSTOCKSHARK 05/01/18 12:01:58 PM
#3888   I'm trying to think of a positive, I Brettj 05/01/18 10:51:43 AM
#3887   I want to amend the analyst coverage on SJSTOCKSHARK 04/30/18 05:21:49 PM
#3886   Maybe they bring in four more research sites wordlender 04/30/18 03:59:38 PM
#3885   Any thoughts on positive developments for BPTH over SJSTOCKSHARK 04/30/18 03:47:41 PM
#3884   Word and Blair, Your positive comments are always SJSTOCKSHARK 04/29/18 05:14:52 PM
#3883   When you google Bio-Path Holdings not much comes wordlender 04/29/18 02:03:11 PM
#3882   Here are two other Bio-Tech that we may SJSTOCKSHARK 04/27/18 02:23:56 PM
#3881   Blair, Sorry but this Board has no effect SJSTOCKSHARK 04/26/18 10:12:02 PM
#3880   I got to thinking and musing while crying blairsoldman 04/26/18 05:01:42 PM
#3879   snug9 Thanks for the quick education. Mt Bobster 04/26/18 11:36:48 AM
#3878   Mt Bobster, do you know the difference between Snug9 04/26/18 03:18:46 AM
PostSubject
© 2018 InvestorsHub.com, Inc.